Targeting kinases for the treatment of inflammatory diseases

Bibliography

• Feldmann M, Williams RO, Paleolog E. What have we learnt from targeted anti-TNF therapy? Ann Rheum Dis 2010;69(Suppl 1):i97-9
   PubMed Web of Science ®Google Scholar
• McCluggage LK, Scholtz JM. Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2010;44(1):135-44
   PubMed Web of Science ®Google Scholar
• Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 2009;84(4 Suppl):14-24
   PubMed Web of Science ®Google Scholar
• Williams MD, Omran ML, Gordon GL. Biologic therapy in Crohn's disease. Mo Med 2009;106(5):356-60
   PubMedGoogle Scholar
• Berger JR, Houff SA, Major EO. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs 2009;1(6):583-9
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 2010;1804(3):433-9
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005;17(6):596-603
   PubMed Web of Science ®Google Scholar
• Dumont FJ, Staruch MJ, Koprak SL, Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990;144(1):251-8
   PubMed Web of Science ®Google Scholar
• Wicker LS, Boltz RC Jr, Matt V, Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur J Immunol 1990;20(10):2277-83
   PubMed Web of Science ®Google Scholar
• Kay JE, Kromwel L, Doe SE, Denyer M. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 1991;72(4):544-9
   PubMed Web of Science ®Google Scholar
• Woltman AM, van der Kooij SW, Coffer PJ, Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003;101(4):1439-45
   PubMed Web of Science ®Google Scholar
• Mita M, Sankhala K, Abdel-Karim I, Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs 2008;17(12):1947-54
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357(25):2562-75
   PubMed Web of Science ®Google Scholar
• Pallet N, Thervet E, Legendre C, Sirolimus early graft nephrotoxicity: clinical and experimental data. Curr Drug Saf 2006;1(2):179-87
   PubMedGoogle Scholar
• Weichhart T, Costantino G, Poglitsch M, The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008;29(4):565-77
   PubMed Web of Science ®Google Scholar
• Boulay JL, O'shea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity 2003;19(2):159-63
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264(5164):1415-21
   PubMed Web of Science ®Google Scholar
• Zhou YJ, Chen M, Cusack NA, Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol Cell 2001;8(5):959-69
   PubMed Web of Science ®Google Scholar
• Bellanne-Chantelot C, Chaumarel I, Labopin M, Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006;108(1):346-52
   PubMed Web of Science ®Google Scholar
• Haan S, Margue C, Engrand A, Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J Immunol 2008;180(2):998-1007
   PubMed Web of Science ®Google Scholar
• Deal watch: dipping into Incyte's JAK-pot. Nat Rev Drug Discov 2010;9(2):94
   Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Collins R, Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2008;184(9):5298-307
   Web of Science ®Google Scholar
• Johnston JA, Kawamura M, Kirken RA, Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994;370(6485):151-3
   PubMed Web of Science ®Google Scholar
• Leonard WJ, Noguchi M, Russell SM, McBride OW. The molecular basis of X-linked severe combined immunodeficiency: the role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c. Immunol Rev 1994;138:61-86
   PubMed Web of Science ®Google Scholar
• Asao H, Okuyama C, Kumaki S, Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001;167(1):1-5
   PubMed Web of Science ®Google Scholar
• Sudbeck EA, Liu XP, Narla RK, Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 1999;5(6):1569-82
   PubMed Web of Science ®Google Scholar
• Changelian PS, Moshinsky D, Kuhn CF, The specificity of JAK3 kinase inhibitors. Blood 2008;111(4):2155-7
   PubMed Web of Science ®Google Scholar
• Stepkowski SM, Erwin-Cohen RA, Behbod F, Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 2002;99(2):680-9
   PubMed Web of Science ®Google Scholar
• Changelian PS, Flanagan ME, Ball DJ, Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302(5646):875-8
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Targeting mast cells in endometriosis with janus kinase 3 inhibitor, JANEX-1. Am J Reprod Immunol 2007;58(2):75-97
   PubMed Web of Science ®Google Scholar
• Buckley RH, Schiff RI, Schiff SE, Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997;130(3):378-87
   PubMed Web of Science ®Google Scholar
• Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000;343(18):1313-24
   PubMed Web of Science ®Google Scholar
• Notarangelo LD, Giliani S, Mazza C, Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol Rev 2000;178:39-48
   PubMed Web of Science ®Google Scholar
• Macchi P, Villa A, Giliani S, Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995;377(6544):65-8
   PubMed Web of Science ®Google Scholar
• Russell SM, Tayebi N, Nakajima H, Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995;270(5237):797-800
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004;3(7):555-64
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Park H, Pesu M, New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway. Curr Opin Rheumatol 2005;17(3):305-11
   PubMed Web of Science ®Google Scholar
• Boggon TJ, Li Y, Manley PW, Eck MJ. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 2005;106(3):996-1002
   PubMed Web of Science ®Google Scholar
• Lucet IS, Fantino E, Styles M, The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006;107(1):176-83
   PubMed Web of Science ®Google Scholar
• Williams NK, Bamert RS, Patel O, Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol 2009;387(1):219-32
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26(1):127-32
   PubMed Web of Science ®Google Scholar
• Jiang JK, Ghoreschi K, Deflorian F, Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R) -4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperi din-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem 2008;51(24):8012-18
   PubMed Web of Science ®Google Scholar
• Rousvoal G, Si MS, Lau M, Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Transpl Int 2006;19(12):1014-21
   PubMed Web of Science ®Google Scholar
• Milici AJ, Kudlacz EM, Audoly L, Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008;10(1):R14
   PubMed Web of Science ®Google Scholar
• Borie DC, Changelian PS, Larson MJ, Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 2005;79(7):791-801
   PubMed Web of Science ®Google Scholar
• Opar A. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat Rev Drug Discov 2010;9(4):257-8
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228(1):273-87
   PubMed Web of Science ®Google Scholar
• Pesu M, Laurence A, Kishore N, Therapeutic targeting of Janus kinases. Immunol Rev 2008;223:132-42
   PubMed Web of Science ®Google Scholar
• Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994;265(5173):808-11
   PubMed Web of Science ®Google Scholar
• Freshney NW, Rawlinson L, Guesdon F, Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 1994;78(6):1039-49
   PubMed Web of Science ®Google Scholar
• Dean JL, Sully G, Clark AR, The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 2004;16(10):1113-21
   PubMed Web of Science ®Google Scholar
• Clark A, Dean J, Tudor C, Saklatvala J. Post-transcriptional gene regulation by MAP kinases via AU-rich elements. Front Biosci 2009;14:847-71
   Web of Science ®Google Scholar
• Lee JC, Laydon JT, McDonnell PC, A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372(6508):739-46
   PubMed Web of Science ®Google Scholar
• O'Keefe SJ, Mudgett JS, Cupo S, Chemical genetics define the roles of p38alpha and p38beta in acute and chronic inflammation. J Biol Chem 2007;282(48):34663-71
   PubMed Web of Science ®Google Scholar
• Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007;1773(8):1358-75
   PubMed Web of Science ®Google Scholar
• Ge B, Gram H, Di Padova F, MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science 2002;295(5558):1291-4
   PubMed Web of Science ®Google Scholar
• Ge B, Xiong X, Jing Q, TAB1beta (transforming growth factor-beta-activated protein kinase 1-binding protein 1beta), a novel splicing variant of TAB1 that interacts with p38alpha but not TAK1. J Biol Chem 2003;278(4):2286-93
   PubMed Web of Science ®Google Scholar
• Salvador JM, Mittelstadt PR, Belova GI, The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 activation pathway. Nat Immunol 2005;6(4):396-402
   PubMed Web of Science ®Google Scholar
• Salvador JM, Mittelstadt PR, Guszczynski T, Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat Immunol 2005;6(4):390-5
   PubMed Web of Science ®Google Scholar
• O'Neill LA. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov 2006;5(7):549-63
   PubMed Web of Science ®Google Scholar
• Zhang J, Shen B, Lin A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci 2007;28(6):286-95
   PubMed Web of Science ®Google Scholar
• Schreiber S, Feagan B, D'Haens G, Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4(3):325-34
   PubMed Web of Science ®Google Scholar
• Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009;60(5):1232-41
   PubMed Web of Science ®Google Scholar
• Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 2009;21(2):317-24
   PubMed Web of Science ®Google Scholar
• Yanagi S, Inatome R, Takano T, Yamamura H. Syk expression and novel function in a wide variety of tissues. Biochem Biophys Res Commun 2001;288(3):495-8
   PubMed Web of Science ®Google Scholar
• Furumoto Y, Nunomura S, Terada T, The FcepsilonRIbeta immunoreceptor tyrosine-based activation motif exerts inhibitory control on MAPK and IkappaB kinase phosphorylation and mast cell cytokine production. J Biol Chem 2004;279(47):49177-87
   PubMed Web of Science ®Google Scholar
• Wong WS, Leong KP. Tyrosine kinase inhibitors: a new approach for asthma. Biochim Biophys Acta 2004;1697(1-2):53-69
   PubMed Web of Science ®Google Scholar
• Wong BR, Grossbard EB, Payan DG, Masuda ES. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 2004;13(7):743-62
   PubMed Web of Science ®Google Scholar
• Ulanova M, Duta F, Puttagunta L, Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis. Expert Opin Ther Targets 2005;9(5):901-21
   PubMed Web of Science ®Google Scholar
• Ruzza P, Biondi B, Calderan A. Therapeutic prospect of Syk inhibitors. Expert Opin Ther Pat 2009;19(10):1361-76
   PubMed Web of Science ®Google Scholar
• Hisamichi H, Naito R, Toyoshima A, Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives. Bioorg Med Chem 2005;13(16):4936-51
   PubMed Web of Science ®Google Scholar
• Villasenor AG, Kondru R, Ho H, Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes. Chem Biol Drug Des 2009;73(4):466-70
   PubMed Web of Science ®Google Scholar
• Pine PR, Chang B, Schoettler N, Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 2007;124(3):244-57
   PubMed Web of Science ®Google Scholar
• Podolanczuk A, Lazarus AH, Crow AR, Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009;113(14):3154-60
   PubMed Web of Science ®Google Scholar
• Karin M. The IkappaB kinase - a bridge between inflammation and cancer. Cell Res 2008;18(3):334-42
   PubMed Web of Science ®Google Scholar
• Uwe S. Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks. Biochem Pharmacol 2008;75(8):1567-79
   PubMed Web of Science ®Google Scholar
• Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007;8(1):49-62
   PubMed Web of Science ®Google Scholar
• Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5(10):749-59
   PubMed Web of Science ®Google Scholar
• Chariot A. The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol 2009;19(8):404-13
   PubMed Web of Science ®Google Scholar
• Senftleben U, Cao Y, Xiao G, Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001;293(5534):1495-9
   PubMed Web of Science ®Google Scholar
• Dejardin E, Droin NM, Delhase M, The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002;17(4):525-35
   PubMed Web of Science ®Google Scholar
• Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3(1):17-26
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Richardson P, NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277(19):16639-47
   PubMed Web of Science ®Google Scholar
• Burke JR, Pattoli MA, Gregor KR, BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 2003;278(3):1450-6
   PubMed Web of Science ®Google Scholar
• Luedde T, Assmus U, Wustefeld T, Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest 2005;115(4):849-59
   PubMed Web of Science ®Google Scholar
• Podolin PL, Callahan JF, Bolognese BJ, Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation. J Pharmacol Exp Ther 2005;312(1):373-81
   PubMed Web of Science ®Google Scholar
• Sommers CD, Thompson JM, Guzova JA, Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation. J Pharmacol Exp Ther 2009;330(2):377-88
   PubMed Web of Science ®Google Scholar
• Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004;23(48):7990-8000
   PubMed Web of Science ®Google Scholar
• Groves T, Smiley P, Cooke MP, Fyn can partially substitute for Lck in T lymphocyte development. Immunity 1996;5(5):417-28
   PubMed Web of Science ®Google Scholar
• Molina TJ, Kishihara K, Siderovski DP, Profound block in thymocyte development in mice lacking p56lck. Nature 1992;357(6374):161-4
   PubMed Web of Science ®Google Scholar
• Straus DB, Weiss A. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 1992;70(4):585-93
   PubMed Web of Science ®Google Scholar
• Goldman FD, Ballas ZK, Schutte B, Defective expression of p56lck in an infant with severe combined immunodeficiency. J Clin Invest 1998;102(2):421-9
   PubMed Web of Science ®Google Scholar
• Hubert P, Bergeron F, Ferreira V, Defective p56Lck activity in T cells from an adult patient with idiopathic CD4+ lymphocytopenia. Int Immunol 2000;12(4):449-57
   PubMed Web of Science ®Google Scholar
• Snow RJ, Cardozo MG, Morwick TM, Discovery of 2-phenylamino-imidazo[4,5-h]isoquinolin-9-ones: a new class of inhibitors of lck kinase. J Med Chem 2002;45(16):3394-405
   PubMed Web of Science ®Google Scholar
• Chen P, Iwanowicz EJ, Norris D, Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency. Bioorg Med Chem Lett 2002;12(21):3153-6
   PubMed Web of Science ®Google Scholar
• Das J, Moquin RV, Lin J, Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56(lck) inhibitors. Bioorg Med Chem Lett 2003;13(15):2587-90
   PubMed Web of Science ®Google Scholar
• Goldberg DR, Butz T, Cardozo MG, Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase. J Med Chem 2003;46(8):1337-49
   PubMed Web of Science ®Google Scholar
• Chen P, Doweyko AM, Norris D, Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity. J Med Chem 2004;47(18):4517-29
   PubMed Web of Science ®Google Scholar
• Maier JA, Brugel TA, Sabat M, Development of N-4,6-pyrimidine-N-alkyl-N'-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase. Bioorg Med Chem Lett 2006;16(14):3646-50
   PubMed Web of Science ®Google Scholar
• Martin MW, Newcomb J, Nunes JJ, Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem 2006;49(16):4981-91
   PubMed Web of Science ®Google Scholar
• Burchat AF, Calderwood DJ, Friedman MM, Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck – a selectivity insight. Bioorg Med Chem Lett 2002;12(12):1687-90
   PubMed Web of Science ®Google Scholar
• Burchat A, Borhani DW, Calderwood DJ, Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett 2006;16(1):118-22
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Fonollosa-Pla V, Brito-Zeron P, Siso-Almirall A. Targeted therapy for systemic sclerosis: how close are we? Nat Rev Rheumatol 2010;6(5):269-78
   PubMed Web of Science ®Google Scholar
• Fedorov O, Muller S, Knapp S. The (un)targeted cancer kinome. Nat Chem Biol 2010;6(3):166-9
   PubMed Web of Science ®Google Scholar
• Katz P, Whalen G, Kehrl JH. Differential expression of a novel protein kinase in human B lymphocytes. Preferential localization in the germinal center. J Biol Chem 1994;269(24):16802-9
   PubMed Web of Science ®Google Scholar
• Zhong J, Gavrilescu LC, Molnar A, GCK is essential to systemic inflammation and pattern recognition receptor signaling to JNK and p38. Proc Natl Acad Sci USA 2009;106(11):4372-7
   PubMed Web of Science ®Google Scholar
• Bouzakri K, Ribaux P, Halban PA. Silencing mitogen-activated protein 4 kinase 4 (MAP4K4) protects beta cells from tumor necrosis factor-alpha-induced decrease of IRS-2 and inhibition of glucose-stimulated insulin secretion. J Biol Chem 2009;284(41):27892-8
   PubMed Web of Science ®Google Scholar
• Bouzakri K, Zierath JR. MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. J Biol Chem 2007;282(11):7783-9
   PubMed Web of Science ®Google Scholar
• Wright JH, Wang X, Manning G, The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol 2003;23(6):2068-82
   PubMed Web of Science ®Google Scholar
• Ohno H, Uemura Y, Murooka H, The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur J Immunol 2008;38(1):283-91
   PubMed Web of Science ®Google Scholar
• Marshall D, Cameron J, Lightwood D, Lawson AD. Blockade of colony stimulating factor-1 (CSF-I) leads to inhibition of DSS-induced colitis. Inflamm Bowel Dis 2007;13(2):219-24
   PubMed Web of Science ®Google Scholar
• Inaba T, Gotoda T, Harada K, Induction of sustained expression of proto-oncogene c-fms by platelet-derived growth factor, epidermal growth factor, and basic fibroblast growth factor, and its suppression by interferon-gamma and macrophage colony-stimulating factor in human aortic medial smooth muscle cells. J Clin Invest 1995;95(3):1133-9
   PubMed Web of Science ®Google Scholar
• Patel S, Player MR. Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease. Curr Top Med Chem 2009;9(7):599-610
   PubMed Web of Science ®Google Scholar
• Wang X, Mader MM, Toth JE, Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA. J Biol Chem 2005;280(19):19298-305
   PubMed Web of Science ®Google Scholar
• Jandhyala DM, Ahluwalia A, Obrig T, Thorpe CM. ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression. Cell Microbiol 2008;10(7):1468-77
   PubMed Web of Science ®Google Scholar
• Manley PW, Drueckes P, Fendrich G, Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010;1804(3):445-53
   PubMed Web of Science ®Google Scholar
• Rix U, Remsing Rix LL, Terker AS, A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. Leukemia 2010;24(1):44-50
   PubMed Web of Science ®Google Scholar
• Al-Qahtani A, Xu Z, Zan H, A role for DRAK2 in the germinal center reaction and the antibody response. Autoimmunity 2008;41(5):341-52
   PubMed Web of Science ®Google Scholar
• Ramos SJ, Hernandez JB, Gatzka M, Walsh CM. Enhanced T cell apoptosis within Drak2-deficient mice promotes resistance to autoimmunity. J Immunol 2008;181(11):7606-16
   PubMed Web of Science ®Google Scholar
• McGargill MA, Choy C, Wen BG, Hedrick SM. Drak2 regulates the survival of activated T cells and is required for organ-specific autoimmune disease. J Immunol 2008;181(11):7593-605
   PubMed Web of Science ®Google Scholar
• Hegedus Z, Czibula A, Kiss-Toth E. Tribbles: a family of kinase-like proteins with potent signalling regulatory function. Cell Signal 2007;19(2):238-50
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Uematsu S, Okamoto T, Enhanced TLR-mediated NF-IL6 dependent gene expression by Trib1 deficiency. J Exp Med 2007;204(9):2233-9
   PubMed Web of Science ®Google Scholar
• Sung HY, Francis SE, Crossman DC, Kiss-Toth E. Regulation of expression and signalling modulator function of mammalian tribbles is cell-type specific. Immunol Lett 2006;104(1-2):171-7
   PubMed Web of Science ®Google Scholar
• Deng J, James CH, Patel L, Human tribbles homologue 2 is expressed in unstable regions of carotid plaques and regulates macrophage IL-10 in vitro. Clin Sci (Lond) 2009;116(3):241-8
   PubMed Web of Science ®Google Scholar
• Liu J, Wu X, Franklin JL, Mammalian Tribbles homolog 3 impairs insulin action in skeletal muscle: role in glucose-induced insulin resistance. Am J Physiol Endocrinol Metab 2009;298(3):E565-76
   PubMed Web of Science ®Google Scholar
• Fabian MA, Biggs WH III, Treiber DK, A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23(3):329-36
   PubMed Web of Science ®Google Scholar
• Dambach DM. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr Top Med Chem 2005;5(10):929-39
   PubMed Web of Science ®Google Scholar
• Cohen SB, Cheng TT, Chindalore V, Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60(2):335-44
   PubMed Web of Science ®Google Scholar
• Schindler JF, Monahan JB, Smith WG. p38 pathway kinases as anti-inflammatory drug targets. J Dent Res 2007;86(9):800-11
   PubMed Web of Science ®Google Scholar
• Liang J, Choi J, Clardy J. Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution. Acta Crystallogr D Biol Crystallogr 1999;55(Pt 4):736-44
   PubMedGoogle Scholar